VANCOUVER, BC / ACCESS Newswire / January 26, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery ...
Teia Collier on MSN
Neurologists highlight eight symptoms you should never overlook
Many people brush off unusual body signals, chalking them up to everyday factors like stress, fatigue, or getting older.
Hosted on MSN
Grandmother, 93, waits eight months for NHS to respond to complaint about Falkirk eye clinic
Elizabeth Connelly and her family had submitted the grievance around her experience in the ophthalmology outpatients clinic at Falkirk Community Hospital at the end of May 2024, but it wasn’t until ...
FDA alerts and updates on the latest drug and device approvals, recalls, and other regulatory developments in ophthalmology.
Up to 189 health conditions could potentially affect your ability to drive, with seven specific conditions that must be declared to the DVLA ...
Background Comorbid autoimmune disorders affect approximately 0.2% of the population. A second autoimmune disease occurs in up to 15% of myasthenia gravis (MG) patients. Objective To evaluate the ...
The U.S. Food and Drug Administration (FDA) on Thursday approved Amgen Inc.’s (NASDAQ: AMGN) Uplinza (inebilizumab-cdon) for generalized myasthenia gravis (gMG). The approval covers adult patients who ...
EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ...
SAN FRANCISCO -- Intravenous efgartigimod (Vyvgart) met its primary endpoint in adults with acetylcholine receptor (AChR) antibody-negative myasthenia gravis, the ADAPT SERON trial showed. At week 4, ...
The myasthenia gravis treatment landscape is expanding with new therapies and mechanisms, enhancing management options. Treatment decisions are complex due to patient heterogeneity and idiosyncratic ...
SPRING HOUSE, Pa., Oct. 29, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced plans to initiate the first head-to-head study comparing FcRn blockers for patients with generalized ...
The EPIC study will evaluate treatment with IMAAVY™ versus efgartigimod in adults with gMG and will include a treatment-switch arm The Company also announced new data from the pivotal Vibrance-MG ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results